Endogenous sex steroids in premenopausal women and risk of breast cancer: the ORDET cohort

Breast Cancer Research

Paola Muti⁵  Holger J Schunemann⁸  Giovanni Blandino⁸  Sara Grioni⁶  Carlo Alberto Abbagnato²  Vittorio Krogh⁶  Franco Berrino¹  Sabina Sieri⁶  Claudia Agnoli⁶  Pedram Razavi⁷  Francesca Sperati³  Eva S Schernhammer⁴ 

[1] Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Via Venezian, 20133 Milan, Italy, EU;Centro Medico Diagnostico Emilia, Via Sorbelli, 40124 Bolgna, Italy, EU;Istituto Nazionale Tumori Regina Elena IRCCS, Via Elio Chianesi, 00144 Roma, Italy, EU;ACR-ITR & LBI-ACR VIEnna, Kundratstrasse, 1100 Wien, Austria, EU;Department of Epidemiology, Harvard School of Public Health, Huntington Avenue, Boston, MA 02115, USA;Nutritional Epidemiology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Via Venezian, 20133 Milan, Italy, EU;Department of Preventive Medicine, University of Southern California, N Soto Street, Los Angeles, CA 90089, USA;Department of Clinical Epidemiology and Biostatistics, McMaster University, Main Street West Hamilton, ON L8S 4K1, Canada

关键词: breast cancer;    premenopausal;    androgens;    estrogens;    sex steroids;   

Others  :  794538
DOI  :  10.1186/bcr3438

 received in 2013-02-14, accepted in 2013-06-18,  发布年份 2013

【 摘 要 】

Introduction

Previous studies showed that higher testosterone levels are associated with greater risk of breast cancer in premenopausal women, but the literature is scant and inconsistent.

Methods

In a prospective nested case-control study of 104 premenopausal women with incident breast cancer and 225 matched controls, all characterized by regular menstrual cycles throughout their lifetime, we measured the concentration of estradiol, total and free testosterone (FT), progesterone, sex hormone-binding globulin (SHBG), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) in blood samples collected on days 20 through 24 of their cycles.

Results

In logistic regression models, the multivariate odds ratios (ORs) of invasive breast cancer for women in the highest tertile of circulating FT compared with the lowest was 2.43 (95% confidence interval (95% CI), 1.15 to 5.10; P_trend = 0.03), whereas for total testosterone, the association had the same direction but was not statistically significant (OR, 1.27; 95% CI, 0.62 to 2.61; P_trend = 0.51). Endogenous progesterone was not statistically associated with breast cancer (OR, 1.16; 95% CI, 0.60 to 2.27; P_trend = 0.75), nor were the other considered hormones.

Conclusions

Consistent with previous prospective studies in premenopausal women and our own earlier investigation, we observed that higher levels of FT are positively associated with breast cancer risk in women with regular menstrual cycles throughout their lifetimes. No evidence of risk was found associated with the other endogenous sex steroids.

【 授权许可】

   
2013 Schernhammer et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Hankinson SE, Eliassen AH: Circulating sex steroids and breast cancer risk in premenopausal women. Horm Cancer 2010, 1:2-10.
• [2]Folkerd EJ, Dowsett M: Influence of sex hormones on cancer progression. J Clin Oncol 2010, 28:4038-4044.
• [3]Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, Dossus L, Lukanova A, Bingham S, Khaw KT, Allen NE, Bueno-de-Mesquita HB, van Gils CH, Grobbee D, Boeing H, Lahmann PH, Nagel G, Chang-Claude J, Clavel-Chapelon F, Fournier A, Thiebaut A, Gonzalez CA, Quiros JR, Tormo MJ, Ardanaz E, Amiano P, Krogh V, Palli D, Panico S, Tumino R, Vineis P, Trichopoulou A, Kalapothaki V, Trichopoulos D, Ferrari P, Norat T, Saracci R, Riboli E: Postmenopausal serum androgens, oestrogens and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition. Endocr Relat Cancer 2005, 12:1071-1082.
• [4]Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, Secreto G, Amiano P, Bingham S, Boeing H, Bueno de Mesquita HB, Chang-Claude J, Clavel-Chapelon F, Fournier A, van Gils CH, Gonzalez CA, Gurrea AB, Critselis E, Khaw KT, Krogh V, Lahmann PH, Nagel G, Olsen A, Onland-Moret NC, Overvad K, Palli D, Panico S, Peeters P, Quiros JR, Roddam A, Thiebaut A, Tjønneland A, Chirlaque MD, Trichopoulou A, Trichopoulos D, Tumino R, Vineis P, Norat T, Ferrari P, Slimani N, Riboli E: Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005, 97:755-765.
• [5]Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW: A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 1994, 18:79-85.
• [6]Wysowski DK, Comstock GW, Helsing KJ, Lau HL: Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol 1987, 125:791-799.
• [7]Helzlsouer KJ, Gordon GB, Alberg AJ, Bush TL, Comstock GW: Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer. Cancer Res 1992, 52:1-4.
• [8]Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE: A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prev 2000, 9:575-579.
• [9]Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS, Wang DY: A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer 1997, 76:401-405.
• [10]Rosenberg CR, Pasternack BS, Shore RE, Koenig KL, Toniolo PG: Premenopausal estradiol levels and the risk of breast cancer: a new method of controlling for day of the menstrual cycle. Am J Epidemiol 1994, 140:518-525.
• [11]Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE: Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 2006, 98:1406-1415.
• [12]Micheli A, Muti P, Secreto G, Krogh V, Meneghini E, Venturelli E, Sieri S, Pala V, Berrino F: Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer 2004, 112:312-318.
• [13]Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schunemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M, Berrino F: Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 2000, 11:635-640.
• [14]Meilahn EN, De Stavola B, Allen DS, Fentiman I, Bradlow HL, Sepkovic DW, Kuller LH: Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 1998, 78:1250-1255.
• [15]Page JH, Colditz GA, Rifai N, Barbieri RL, Willett WC, Hankinson SE: Plasma adrenal androgens and risk of breast cancer in premenopausal women. Cancer Epidemiol Biomarkers Prev 2004, 13:1032-1036.
• [16]Tworoger SS, Missmer SA, Eliassen AH, Spiegelman D, Folkerd E, Dowsett M, Barbieri RL, Hankinson SE: The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women. Cancer Epidemiol Biomarkers Prev 2006, 15:967-971.
• [17]Muti P, Stanulla M, Micheli A, Krogh V, Freudenheim JL, Yang J, Schunemann HJ, Trevisan M, Berrino F: Markers of insulin resistance and sex steroid hormone activity in relation to breast cancer risk: a prospective analysis of abdominal adiposity, sebum production, and hirsutism (Italy). Cancer Causes Control 2000, 11:721-730.
• [18]Schernhammer ES, Berrino F, Krogh V, Secreto G, Micheli A, Venturelli E, Grioni S, Sempos CT, Cavalleri A, Schunemann HJ, Strano S, Muti P: Urinary 6-sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort. Cancer Epidemiol Biomarkers Prev 2010, 19:729-737.
• [19]Sieri S, Muti P, Claudia A, Berrino F, Pala V, Grioni S, Abagnato CA, Blandino G, Contiero P, Schunemann HJ, Krogh V: Prospective study on the role of glucose metabolism in breast cancer occurrence. Int J Cancer 2011, 130:921-929.
• [20]Berrino F, Muti P, Micheli A, Bolelli G, Krogh V, Sciajno R, Pisani P, Panico S, Secreto G: Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996, 88:291-296.
• [21]Berrino F, Pisani P, Muti P: Prospective study of hormones and diet in the aetiology of breast cancer. In Diet, Hormones, and Cancer: Methodological Issues for Prospective Studies. Volume IARC Technical Report Number 4. Edited by Riboli E, Saracci R. Lyons: IARC; 1988:34-38.
• [22]Parkin DM, Whelan S, Ferlay J: Cancer incidence in five continents, vol. VII. In IARC Scientific Publications Number 143. Lyons: IARC; 1997.
• [23]Waterhouse J, Muir C, Shanmugaratnam K: IARC Scientific Publications. Lyons: IARC; 1982.
• [24]Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN, Hankinson SE: Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol Biomarkers Prev 2006, 15:972-978.